Design and immunogenicity of a quadrivalent mRNA vaccine targeting HSV-2 with comparative evaluation of co-formulated and admixed formulations
The quadrivalent mRNA vaccine provides strong and durable protection against both primary and latent infection, supporting its potential as a promising candidate for the prevention of genital herpes.
Authors
- Youngran Cho (ORCID: https://orcid.org/0000-0002-7022-0338)
- Dahyeon Ha (ORCID: https://orcid.org/0009-0001-1859-0454)
- Subin Yoon (ORCID: https://orcid.org/0000-0002-7970-1664)
- Hye-Ra Lee (ORCID: https://orcid.org/0000-0003-3815-3291)
- Jae‐Hwan Nam (ORCID: https://orcid.org/0000-0002-0974-4343)
- Yu‐Sun Lee (ORCID: https://orcid.org/0000-0001-8358-984X)
- Yeongjun Kim
- Hyo‐Jung Park (ORCID: https://orcid.org/0000-0002-1601-7638)
- Sang‐In Park (ORCID: https://orcid.org/0000-0001-8662-1999)
- K.-H. Cho
- Gahyun Roh
- Ji Sun Lee (ORCID: https://orcid.org/0000-0002-2393-010X)
- Chanwoo Lee (ORCID: https://orcid.org/0009-0003-0764-4861)
- Seonghyun Lee (ORCID: https://orcid.org/0009-0003-7355-3570)
- Ayoung Oh
Institutions
- Daegu Haany University (KR)
- Sejong University (KR)
- The Catholic University of Korea Bucheon St. Mary's Hospital (KR)
- Korea University (JP)
- Catholic University of Korea (KR)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-12-05
- DOI
- https://doi.org/10.3389/fimmu.2025.1712691
- Citations
- 1
- Primary Topic
- Herpesvirus Infections and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.35
Funders
- National Research Foundation
- Ministry of Food and Drug Safety
- National Research Foundation of Korea